|Articles|June 15, 2016

ERT Introduces Centralized DLCO Services for Respiratory Trials

ERT introduces its Centralized DLCO Services for assessing diffusing capacity of the lungs for carbon monoxide data in respiratory trials.

ERT introduces its Centralized DLCO Services for assessing diffusing capacity of the lungs for carbon monoxide data in respiratory trials. These services allow for near real time evaluation, notifications, expert overread, data reconciliation and reporting. Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
September 9th 2025
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
September 9th 2025
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
September 9th 2025
How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
September 8th 2025

ERT Introduces Centralized DLCO Services for Respiratory Trials

Newsletter

Related Articles

Trending on Applied Clinical Trials Online

AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer

Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19

Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC

Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial

Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer